Developer docs
API playgroundTry for free, no card

Search company profiles

Rapt Therapeutics

Full company profile

uuid00021zk

Namestring
Rapt Therapeutics
Legal namestring
RAPT Therapeutics, Inc.
Websiteurl
rapt.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Rapt Therapeutics was a clinical-stage biopharmaceutical company focused on the discovery and development of immunology-based therapeutics for inflammatory and immunological diseases. Founded in 2015 and headquartered in South San Francisco, California, the company was publicly traded on NASDAQ under the ticker RAPT prior to its March 2026 acquisition by GSK plc. Its lead asset, ozureprubart (formerly RPT904/JYB1904), is a novel half-life extended monoclonal antibody designed to bind free human IgE, a key driver of allergic diseases. Compared to first-generation anti-IgE therapy omalizumab (Xolair), ozureprubart demonstrated extended pharmacokinetic and pharmacodynamic properties supporting potential dosing every 8-12 weeks versus every 2-4 weeks for omalizumab, and offered a path to treat patients currently ineligible for omalizumab due to high IgE levels or body weight. The company also held a granted patent on fused ring imidazole compounds acting as TNF-alpha modulators with applications across cancer, autoimmune, metabolic, and neurological disorders.

Rapt's pipeline targeted two primary indications: food allergy (peanut, milk, egg, cashew, walnut) and chronic spontaneous urticaria (CSU). A Phase 2 trial in 137 CSU patients demonstrated comparable efficacy and safety to omalizumab with durable effects after a single dose, and the FDA cleared an Investigational New Drug application in September 2025 to proceed to the Phase 2b prestIgE food allergy trial, which was initiated in October 2025 across sites in the U.S., Canada, and Australia with results expected in 2027. Rapt partnered with Shanghai Jeyou Pharmaceutical for development and commercialization in China, where the asset advanced to Phase 3.

As a pre-revenue clinical-stage company, Rapt generated no product sales and funded operations through multiple capital raises totaling approximately $668.7 million across public offerings in June 2021 ($143.7M), November 2022 ($75M), and October 2025 ($250M), plus private placements in May 2022 ($50M PIPE led by Redmile Group) and December 2024 ($150M). The company was acquired by GSK plc in January 2026 for approximately $2.2 billion ($58 per share, a ~65.2% premium), with the deal closing in March 2026 and RAPT delisting from Nasdaq to become a wholly owned subsidiary of GSK.

Short descriptiontext

Rapt Therapeutics was a clinical-stage biopharmaceutical company developing ozureprubart, a long-acting anti-IgE monoclonal antibody for food allergy and chronic spontaneous urticaria. The pre-revenue South San Francisco-based company was acquired by GSK in 2026 for $2.2 billion.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, monoclonal antibody therapy, anti-IgE therapeutics, allergic disease treatments, immunology drug development
Industry2 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Immunology Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Revenue
TypeOne Time License
Description

RAPT Therapeutics was a clinical-stage biopharmaceutical company with no commercialized products. The company was developing ozureprubart for food allergy and chronic spontaneous urticaria. Revenue was expected to come from product sales following regulatory approval. The company was acquired by GSK in March 2026 before commercializing any products.

rapt.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

RAPT Therapeutics was a clinical-stage biopharmaceutical company developing immunology-based therapeutics for inflammatory and immunological diseases. Its lead product candidate, ozureprubart (RPT904/JYB1904), is a half-life extended anti-IgE monoclonal antibody in Phase 2b development for food allergy protection and previously tested in Phase 2 for chronic spontaneous urticaria, with future revenue expected from product sales following regulatory approval.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase 2 trial in 137 CSU patients showed durable efficacy out to 16 weeks comparable to omalizumab dosed every 4 weeks
+2 more records
Product overview1 text field

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for inflammatory and immunological diseases. The company's primary product is ozureprubart (formerly RPT904/JYB1904), a long-acting anti-IgE monoclonal antibody in Phase 2b development for food allergy protection and previously completed Phase 2 trials for chronic spontaneous urticaria (CSU). The company was acquired by GSK in January 2026 for approximately $2.2 billion.

Product and service1 record
1Ozureprubart (RPT904/JYB1904)
CategoryAnti-IgE Monoclonal Antibody Biologic
Description

A novel half-life extended monoclonal antibody (mAb) designed to bind free human IgE for the treatment of allergic inflammatory diseases including food allergy and chronic spontaneous urticaria. Designed to be dosed every 8-12 weeks versus every 2-4 weeks for omalizumab (Xolair), with potential to treat patients currently ineligible for omalizumab due to high IgE or body weight.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Shanghai Jeyou Pharmaceutical
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-20
Description

RAPT Therapeutics partnered with Shanghai Jeyou Pharmaceutical for the development of RPT904 (JYB1904/ozureprubart) in China. The partnership achieved positive topline data from a Phase 2 trial in chronic spontaneous urticaria in October 2025, demonstrating comparable efficacy and safety to omalizumab with durable effects after a single dose. Jeyou advanced RPT904 to Phase 3 development in China.

globenewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-developers of Dupixent (dupilumab), a leading IL-4/IL-13 biologic approved across multiple type-2 inflammatory indications including CSU-adjacent conditions. Dupixent represents the most relevant therapeutic competitor and emerging standard of care in several allergic indications RAPT targets.

2Alladapt Immunotherapeutics
TypeEmerging player
Description

Clinical-stage company developing multi-food oral immunotherapy (ADP101) covering peanut plus other priority food allergens. Targets the same multi-food allergy patient population as ozureprubart's prestIgE trial.

TypeDirect peer
Description

Developer of Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. Aimmune competes directly in RAPT's food allergy indication with a fundamentally different mechanism (desensitization vs. IgE blockade).

TypeBroad incumbent
Description

Through Amgen partnership, markets Tezspire (tezepelumab) in severe asthma and has broader respiratory/immunology franchise. AstraZeneca competes in the same prescriber base and biologic allergic disease treatment paradigm as ozureprubart.

TypeRegional player
Description

Dermatology-focused biopharma with atopic dermatitis portfolio (Adbry/adtralza). While more regionally concentrated, LEO Pharma represents an adjacent competitor in the broader type-2 inflammation treatment landscape relevant to chronic allergic diseases.

TypeOthers
Description

Acquirer of RAPT Therapeutics for $2.2B in 2026. GSK is the parent company and now controls global development and commercialization of ozureprubart outside of greater China, making it the most strategically relevant entity for understanding post-acquisition value capture.

TypeBroad incumbent
Description

Global biopharmaceutical company with immunology franchise including Cimzia and growing presence in atopic diseases. Operates in overlapping prescriber and payer ecosystems in chronic allergic conditions targeted by ozureprubart.

TypeEmerging player
Description

Developer of Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. DBV competes in the same pediatric/adolescent food allergy treatment market with a non-injectable alternative modality.

TypeBroad incumbent
Description

Established allergy immunotherapy company offering subcutaneous and sublingual immunotherapy products across a range of allergens. Operates in adjacent allergy treatment paradigms and shares allergist prescriber relationships with RAPT.

TypeDirect peer
Description

Co-developers and marketers of omalizumab (Xolair), the incumbent anti-IgE monoclonal antibody and direct competitive benchmark for ozureprubart across CSU, food allergy, and severe asthma. Any ozureprubart commercial profile is measured against Xolair's safety, efficacy, and real-world experience base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rapt Therapeutics

Immunology Biopharmaceutical Therapeuticsrapt.com

Rapt Therapeutics was a clinical-stage biopharmaceutical company developing ozureprubart, a long-acting anti-IgE monoclonal antibody for food allergy and chronic spontaneous urticaria. The pre-revenue South San Francisco-based company was acquired by GSK in 2026 for $2.2 billion.

What Rapt Therapeutics does

Rapt Therapeutics was a clinical-stage biopharmaceutical company focused on the discovery and development of immunology-based therapeutics for inflammatory and immunological diseases. Founded in 2015 and headquartered in South San Francisco, California, the company was publicly traded on NASDAQ under the ticker RAPT prior to its March 2026 acquisition by GSK plc. Its lead asset, ozureprubart (formerly RPT904/JYB1904), is a novel half-life extended monoclonal antibody designed to bind free human IgE, a key driver of allergic diseases. Compared to first-generation anti-IgE therapy omalizumab (Xolair), ozureprubart demonstrated extended pharmacokinetic and pharmacodynamic properties supporting potential dosing every 8-12 weeks versus every 2-4 weeks for omalizumab, and offered a path to treat patients currently ineligible for omalizumab due to high IgE levels or body weight. The company also held a granted patent on fused ring imidazole compounds acting as TNF-alpha modulators with applications across cancer, autoimmune, metabolic, and neurological disorders.

Rapt's pipeline targeted two primary indications: food allergy (peanut, milk, egg, cashew, walnut) and chronic spontaneous urticaria (CSU). A Phase 2 trial in 137 CSU patients demonstrated comparable efficacy and safety to omalizumab with durable effects after a single dose, and the FDA cleared an Investigational New Drug application in September 2025 to proceed to the Phase 2b prestIgE food allergy trial, which was initiated in October 2025 across sites in the U.S., Canada, and Australia with results expected in 2027. Rapt partnered with Shanghai Jeyou Pharmaceutical for development and commercialization in China, where the asset advanced to Phase 3.

As a pre-revenue clinical-stage company, Rapt generated no product sales and funded operations through multiple capital raises totaling approximately $668.7 million across public offerings in June 2021 ($143.7M), November 2022 ($75M), and October 2025 ($250M), plus private placements in May 2022 ($50M PIPE led by Redmile Group) and December 2024 ($150M). The company was acquired by GSK plc in January 2026 for approximately $2.2 billion ($58 per share, a ~65.2% premium), with the deal closing in March 2026 and RAPT delisting from Nasdaq to become a wholly owned subsidiary of GSK.

Rapt Therapeutics firmographics

Firmographics
Name
Rapt Therapeutics
Legal name
RAPT Therapeutics, Inc.
Website
https://rapt.com
Company type
Public
Founded year
2015
Operating status
Acquired
Headcount range
101–250 employees
Short description
Rapt Therapeutics was a clinical-stage biopharmaceutical company developing ozureprubart, a long-acting anti-IgE monoclonal antibody for food allergy and chronic spontaneous urticaria. The pre-revenue South San Francisco-based company was acquired by GSK in 2026 for $2.2 billion.
Ownership category
akta.pro rank

Rapt Therapeutics industry classification

Industry
Product category
Immunology Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Clinical-stage biopharmaceuticals
  • Monoclonal antibody therapy
  • Anti-IgE therapeutics
  • Allergic disease treatments
  • Immunology drug development

Where Rapt Therapeutics is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Rapt Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Biopharmaceutical Product Revenue: RAPT Therapeutics was a clinical-stage biopharmaceutical company with no commercialized products. The company was developing ozureprubart for food allergy and chronic spontaneous urticaria. Revenue was expected to come from product sales following regulatory approval. The company was acquired by GSK in March 2026 before commercializing any products.

Go-to-market motion1 record

Marketing channels3 records

Rapt Therapeutics product offering

Product offering

Core offering

RAPT Therapeutics was a clinical-stage biopharmaceutical company developing immunology-based therapeutics for inflammatory and immunological diseases. Its lead product candidate, ozureprubart (RPT904/JYB1904), is a half-life extended anti-IgE monoclonal antibody in Phase 2b development for food allergy protection and previously tested in Phase 2 for chronic spontaneous urticaria, with future revenue expected from product sales following regulatory approval.

Product overview

RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for inflammatory and immunological diseases. The company's primary product is ozureprubart (formerly RPT904/JYB1904), a long-acting anti-IgE monoclonal antibody in Phase 2b development for food allergy protection and previously completed Phase 2 trials for chronic spontaneous urticaria (CSU). The company was acquired by GSK in January 2026 for approximately $2.2 billion.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ozureprubart (RPT904/JYB1904) A novel half-life extended monoclonal antibody (mAb) designed to bind free human IgE for the treatment of allergic inflammatory diseases including food allergy and chronic spontaneous urticaria. Designed to be dosed every 8-12 weeks versus every 2-4 weeks for omalizumab (Xolair), with potential to treat patients currently ineligible for omalizumab due to high IgE or body weight.

Quantifiable outcome

  • Phase 2 trial in 137 CSU patients showed durable efficacy out to 16 weeks comparable to omalizumab dosed every 4 weeks
  • +2 more outcomes

Companies that use Rapt Therapeutics

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Rapt Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Rapt Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Shanghai Jeyou PharmaceuticalcoreStrategic or Co-development Partner · 20 October 2025RAPT Therapeutics partnered with Shanghai Jeyou Pharmaceutical for the development of RPT904 (JYB1904/ozureprubart) in China. The partnership achieved positive topline data from a Phase 2 trial in chronic spontaneous urticaria in October 2025, demonstrating comparable efficacy and safety to omalizumab with durable effects after a single dose. Jeyou advanced RPT904 to Phase 3 development in China.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Rapt Therapeutics competitors and assessment

Company assessment

Direct peers

  • Sanofi / Regeneron: Co-developers of Dupixent (dupilumab), a leading IL-4/IL-13 biologic approved across multiple type-2 inflammatory indications including CSU-adjacent conditions. Dupixent represents the most relevant therapeutic competitor and emerging standard of care in several allergic indications RAPT targets.
  • Aimmune Therapeutics (Nestlé Health Science): Developer of Palforzia, the first FDA-approved oral immunotherapy for peanut allergy. Aimmune competes directly in RAPT's food allergy indication with a fundamentally different mechanism (desensitization vs. IgE blockade).
  • Genentech (Roche) / Novartis: Co-developers and marketers of omalizumab (Xolair), the incumbent anti-IgE monoclonal antibody and direct competitive benchmark for ozureprubart across CSU, food allergy, and severe asthma. Any ozureprubart commercial profile is measured against Xolair's safety, efficacy, and real-world experience base.

Emerging players

  • Alladapt Immunotherapeutics: Clinical-stage company developing multi-food oral immunotherapy (ADP101) covering peanut plus other priority food allergens. Targets the same multi-food allergy patient population as ozureprubart's prestIgE trial.
  • DBV Technologies: Developer of Viaskin, an epicutaneous immunotherapy patch for peanut and other food allergies. DBV competes in the same pediatric/adolescent food allergy treatment market with a non-injectable alternative modality.

Broad incumbents

  • AstraZeneca: Through Amgen partnership, markets Tezspire (tezepelumab) in severe asthma and has broader respiratory/immunology franchise. AstraZeneca competes in the same prescriber base and biologic allergic disease treatment paradigm as ozureprubart.
  • UCB: Global biopharmaceutical company with immunology franchise including Cimzia and growing presence in atopic diseases. Operates in overlapping prescriber and payer ecosystems in chronic allergic conditions targeted by ozureprubart.
  • Stallergenes Greer: Established allergy immunotherapy company offering subcutaneous and sublingual immunotherapy products across a range of allergens. Operates in adjacent allergy treatment paradigms and shares allergist prescriber relationships with RAPT.

Regional players

  • LEO Pharma: Dermatology-focused biopharma with atopic dermatitis portfolio (Adbry/adtralza). While more regionally concentrated, LEO Pharma represents an adjacent competitor in the broader type-2 inflammation treatment landscape relevant to chronic allergic diseases.

Others

  • GlaxoSmithKline (GSK): Acquirer of RAPT Therapeutics for $2.2B in 2026. GSK is the parent company and now controls global development and commercialization of ozureprubart outside of greater China, making it the most strategically relevant entity for understanding post-acquisition value capture.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Rapt Therapeutics social profiles

Digital presence

Rapt Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rapt Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Rapt Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rapt Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rapt Therapeutics

What does Rapt Therapeutics do?

RAPT Therapeutics was a clinical-stage biopharmaceutical company developing immunology-based therapeutics for inflammatory and immunological diseases. Its lead product candidate, ozureprubart (RPT904/JYB1904), is a half-life extended anti-IgE monoclonal antibody in Phase 2b development for food allergy protection and previously tested in Phase 2 for chronic spontaneous urticaria, with future revenue expected from product sales following regulatory approval.

Is Rapt Therapeutics a public or private company?

Rapt Therapeutics is a public company. It is classified as public and is currently acquired.

When was Rapt Therapeutics founded?

Rapt Therapeutics was founded in 2015. It employs 101 to 250 people.

Where is Rapt Therapeutics based?

Rapt Therapeutics is headquartered in South San Francisco, United States, in the North America region.

How does Rapt Therapeutics make money?

One revenue line is on record: biopharmaceutical Product Revenue.

Who are Rapt Therapeutics's main competitors?

Direct peers on record are Sanofi / Regeneron, Aimmune Therapeutics (Nestlé Health Science) and Genentech (Roche) / Novartis. Emerging players are Alladapt Immunotherapeutics and DBV Technologies. Broad incumbents are AstraZeneca, UCB and Stallergenes Greer. LEO Pharma is listed as a regional player. GlaxoSmithKline (GSK) is listed as an others.

Does Rapt Therapeutics have an API?

No public API is recorded for Rapt Therapeutics.

What industry is Rapt Therapeutics in?

Rapt Therapeutics's product category is Immunology Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
European BiotechnologyGSK announces plan to axe UK Stevenage R&D hub, moving to CambridgeGSK announced plans to close its UK R&D headquarters in Stevenage and move operations to a new 300,000-square-foot site in Cambridge, with a phased employee move by 2029. The company also unveiled a three-year cost-cutting programme targeting £1.9 billion in annual savings by 2029, and plans to invest £400 million over three years.PR NewswireFood Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsightThe food allergy market is projected to grow from $2.7 billion in 2025 to $2.7 billion by 2036 at a 9.4% CAGR. Emerging therapies include DBV's Viaskin patch, Novartis' remibrutinib, and GSK's ozureprubart, with Phase III trials underway. Launches are expected to intensify competition and drive steady growth.European Biotechnology8 European VC firms to watch in 2026Eight European VC firms are profiled for 2026, including Jeito Capital, Sofinnova Partners, and Medicxi, with fund sizes and recent exits. The list highlights firms that closed new biotech funds in the past year, such as Jeito II at $1.2 billion and Medicxi V at €500 million. The firms are positioned as shaping the continent's investment landscape amid tighter capital.InsidermediaHealthcare M&A stalls in a “more cautious environment”UK healthcare M&A activity declined to 53 deals in Q1 2026, down from 72 in the same period last year, as tight financing conditions, elevated interest rates, staffing cost pressures, and geopolitical tensions created a more cautious investor environment. Large-cap deals included GSK's £1.7bn acquisition of RAPT Therapeutics and Smith & Nephew's £450m acquisition of Integrity Orthopaedics. Despite the volume decline, resilient demand for defensive, needs-led healthcare assets continues to underpin activity, particularly in elderly care, pharma, pharmacies, and medical devices.FierceBiotechWhich blockbuster is GSK gunning for next? CEO Miels is looking to oncologyGSK CEO Luke Miels outlined the company's dealmaking strategy focused on acquiring targets that can improve upon existing blockbuster drugs, with oncology identified as a particularly promising area. Recent deals include the $2.2 billion acquisition of Rapt Therapeutics and the $950 million purchase of Canadian biotech 35Pharma, both aimed at addressing underserved or suboptimal treatments. Miels declined to specify which additional blockbusters GSK is pursuing but indicated there are multiple areas with established product portfolios that could be improved.MassbioMarch Update: Antibody Industry Trends (Q1 2026 Insights, Trends & Analysis)Biointron Biological published its Q1 2026 Antibody Industry Trends report covering January through March 2026, documenting three novel monoclonal antibody drugs approved in China (Libevitug for chronic hepatitis D, Retlirafusp Alfa for gastric cancer, and Amdokitug for plaque psoriasis) and major bispecific/trispecific antibody deals totaling billions of dollars. The top five deals include Innovent Biologics' $8.5 billion collaboration with Eli Lilly, AbbVie's $5.6 billion licensing agreement with RemeGen Biosciences, Sanofi's $2.56 billion deal with Earendil Labs, GSK's $2.2 billion acquisition of RAPT Therapeutics, and Gilead Sciences' $2.18 billion acquisition of Ouro Medicines. The report also tracks startup funding rounds, early developability trends in antibody discovery, multiple myeloma treatment research, and upcoming regulatory approval decisions for Q2 2026.openPR.comPeanut Allergy Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsightDelveInsight's Peanut Allergy Pipeline Insight 2026 report highlights over 12 companies actively developing more than 15 pipeline therapies for peanut allergy treatment, with recent clinical trial activity reported in March 2026 including ALK-Abello A/S initiating a phase I/II dose-escalation trial, DBV Technologies conducting a Phase 3 safety study of DBV712 in children aged 1-3, and RAPT Therapeutics Inc. announcing a phase 2B study for RPT904. The report covers drugs across various stages and mechanisms of action including Remibrutinib (Novartis), VLP Peanut (Allergy Therapeutics), and INT301 (Intrommune Therapeutics).YahooThis Biotech Was Quietly Bought Before a $58 Per Share TakeoutFCPM III Services B.V. disclosed purchasing 1,489,096 RAPT Therapeutics shares worth approximately $46.24 million during the fourth quarter of 2025, before GSK acquired RAPT Therapeutics for $58 per share in February 2026. The all-cash deal valued at roughly $2.2 billion represented a nearly 90% premium over the estimated average purchase price of around $31 per share. The acquisition closed this quarter, transforming what appeared to be a clinical-stage biotech conviction bet into a takeout arbitrage with a defined ceiling and locked-in gains.The Motley FoolThis Biotech Was Quietly Bought Before a $58 Per Share TakeoutOn February 17, 2026, FCPM III Services B.V. disclosed it had purchased 1,489,096 RAPT Therapeutics shares for approximately $46.24 million during the fourth quarter. GSK acquired RAPT Therapeutics earlier in February 2026 for $58 per share in a deal valued at roughly $2.2 billion, representing a near 90% premium over the estimated purchase price of around $31 per share. The article notes that the position was built on underlying conviction in the asset before the acquisition timeline compressed, turning what looked like a clinical-stage biotech bet into a takeout arbitrage with a defined ceiling.Investing.comGSK expands Arexvy RSV vaccine approval to adults 18-49 By Investing.comThe FDA has expanded GSK's Arexvy RSV vaccine approval to include adults aged 18-49 at increased risk for RSV-related lower respiratory tract disease, following a Phase IIIb trial that demonstrated non-inferior immune response compared to adults 60 and older. The approval potentially opens the vaccine to an estimated 21 million U.S. adults with at least one risk factor for severe RSV infection. GSK has also recently completed a $2.2 billion acquisition of RAPT Therapeutics and entered a $300 million license agreement with Alfasigma for linerixibat.